<DOC>
	<DOCNO>NCT00460512</DOCNO>
	<brief_summary>The purpose study explore tolerability , safety effectiveness flexibly dose paliperidone extend release ( ER ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) previously unsuccessfully treated oral antipsychotic medication .</brief_summary>
	<brief_title>An Efficacy , Safety And Tolerability Study Flexibly Dosed Paliperidone Extended Release ( ER ) Participants With Schizophrenia</brief_title>
	<detailed_description>This non-randomized ( study drug assign chance ) , single arm , multicenter ( one hospital medical school team work medical research study ) 6-month study . Participants transition effective dose paliperidone ER oral antipsychotic medication due lack efficacy , lack tolerability safety , lack compliance reason . A transition period maximum 4 week allow . Throughout study , participant receive flexible dose 3 12 milligram ( mg ) paliperidone daily orally 6 month . Adjustment dosage do Investigator 's discretion , base individual participant 's clinical response tolerability study drug dosage . Participants complete 6-month study would like continue eligible enrol extension phase paliperidone ER available . The start dose extension phase end 6-month study may change throughout extension period . The extension phase consist main extension phase ( end End Main Extension Phase Visit ) modify extension phase ( end End Study Visit ) . Efficacy primarily evaluate positive negative syndrome scale ( PANSS ) . Safety primarily evaluate Extrapyramidal Symptom Rating Scale ( ESRS ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participant meet Diagnostic Statistical Manual Mental Disorders ( Edition 4 ) criterion schizophrenia Participant previously nonacute ( antipsychotic medication use treatment schizophrenia Clinical Global ImpressionSeverity [ CGIS ] change less equal 1 past 4 week enrollment ) give adequate dose appropriate oral antipsychotic adequate period time prior enrollment , previous treatment consider unsuccessful due one follow reason : lack effectiveness , lack tolerability safety , lack compliance and/or reason switch another antipsychotic medication Participant healthy basis physical examination vital sign screen Female participant must postmenopausal least 1 year , surgically sterile , abstinent , , sexually active , agree practice effective method birth control entry throughout study Participants must willing able fill selfadministered questionnaire Participants clozapine , conventional depot neuroleptic risperidone longacting injection last 3 month Participants serious unstable medical condition , include know clinically relevant laboratory abnormality Participants history current symptom tardive dyskinesia ( twitch jerk movement control face , tongue , part body ) neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) Participants judge high risk adverse event , violence selfharm Participants current use know history ( past 6 month ) substance dependence accord Diagnostic Statistical Manual Mental Disorders ( Edition 4 ) Criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Flexible dosing</keyword>
	<keyword>Non-acute patient</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Atypical</keyword>
	<keyword>INVEGA</keyword>
</DOC>